Bio-Techne Shareholders Approve Merck KGaA Acquisition

By Bobby Samwell • Thursday, September 24 10:47 • Permanent Link

Bio-Techne shareholders approved the company’s planned acquisition by Merck KGaA, Darmstadt, Germany, at a special meeting on Sept. 23, 2026, moving the deal another step closer to completion.

The company said the final voting results will be filed later in a Form 8-K. Bio-Techne also said the Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern time on Sept. 18, 2026.

Bio-Techne continues to expect the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals and other customary closing conditions.

The company emphasized the shareholder vote as a key milestone, with CEO Kim Kelderman saying the deal would deliver “substantial, near-term cash value” to shareholders.

Bio-Techne said it generated more than $1.2 billion in net sales in fiscal 2025, operates in 34 locations worldwide, and employs more than 3,000 people. Its portfolio includes more than 500,000 products used in research, biopharma, biotechnology, and clinical diagnostics. Following these announcements, the company's shares moved -0.04%, and are now trading at a price of $72.52. For the full picture, make sure to review BIO-TECHNE Corp's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.